文献速递乳腺癌

曲妥珠单抗辅助治疗后奈拉替尼治疗HER2阳性乳腺癌的总生存期(ExteNET):一项随机、双盲、安慰剂对照的3期试验

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Eur J Cancer · 2023-02-10

ExteNET试验纳入2840例完成新辅助和辅助化疗联合曲妥珠单抗治疗的早期HER2阳性乳腺癌女性,随机接受口服奈拉替尼240 mg/日或安慰剂治疗1年。中位随访8.1年后,奈拉替尼组与安慰剂组8年总生存率分别为90.1%和90.2%,分层风险比为0.95(95%CI 0.75-1.21;P=0.6914),延长辅助治疗阶段两组总生存期相当。

要点

  • 中位随访8.1年,奈拉替尼组死亡127例(8.9%),安慰剂组死亡137例(9.6%)。
  • 8年总生存率奈拉替尼组90.1%(95%CI 88.3-91.6),安慰剂组90.2%(95%CI 88.4-91.7)。
  • 分层风险比0.95(95%CI 0.75-1.21;P=0.6914),两组总生存期相当。

核心结论

  • 在早期HER2阳性乳腺癌女性中,中位随访8.1年后,延长辅助治疗阶段奈拉替尼组与安慰剂组的总生存期相当。

研究设计与样本

  • 国际、随机、双盲、安慰剂对照的3期试验(ExteNET,NCT00878709)。
  • 纳入18岁及以上、1-3c期(后修订为2-3c期)HER2阳性乳腺癌女性,已完成新辅助和辅助化疗联合曲妥珠单抗治疗。
  • 2840例女性随机接受口服奈拉替尼240 mg/日(n=1420)或安慰剂(n=1420)治疗1年。
  • 随机分层因素为激素受体状态(HR阳性 vs HR阴性)、淋巴结状态(0、1-3或4+)和曲妥珠单抗方案(序贯 vs 与化疗同步)。
  • 总生存期按意向治疗分析。

主要发现

  • 2009年7月9日至2011年10月24日期间入组,奈拉替尼组1420例,安慰剂组1420例。
  • 中位随访8.1年(IQR 7.0-8.8),意向治疗人群中奈拉替尼组死亡127例(8.9%),安慰剂组死亡137例(9.6%)。
  • 8年总生存率奈拉替尼组为90.1%(95%CI 88.3-91.6),安慰剂组为90.2%(95%CI 88.4-91.7)。
  • 分层风险比为0.95(95%CI 0.75-1.21;P=0.6914)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved invasive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET. METHODS: In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1-3c (amended to stage 2-3c) HER2-positive breast cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab were eligible. Patients were randomly assigned to oral neratinib 240 mg/day or placebo for 1 year. Randomisation was stratified according to hormone receptor (HR) status (HR-positive vs. HR-negative), nodal status (0, 1-3 or 4+), and trastuzumab regimen (sequentially vs. concurrently with chemotherapy). Overall survival was analysed by intention to treat. ExteNET is registered (Clinicaltrials.gov: NCT00878709) and is complete. RESULTS: Between July 9, 2009, and October 24, 2011, 2840 women received neratinib (n = 1420) or placebo (n = 1420). After a median follow-up of 8.1 (IQR, 7.0-8.8) years, 127 patients (8.9%) in the neratinib group and 137 patients (9.6%) in the placebo group in the intention-to-treat population had died. Eight-year overall survival rates were 90.1% (95% CI 88.3-91.6) with neratinib and 90.2% (95% CI 88.4-91.7) with placebo (stratified hazard ratio 0.95; 95% CI 0.75-1.21; p = 0.6914). CONCLUSIONS: Overall survival in the extended adjuvant setting was comparable for neratinib and placebo after a median follow-up of 8.1 years in women with early-stage HER2-positive breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Holmes FA, Moy B, Delaloge S, et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. Eur J Cancer. 2023. PMID: 36898233. doi:10.1016/j.ejca.2023.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。